Clinical trial NCT04930744: Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)
Official title: A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Tuberculosis
Pulmonary Tuberculosis
HIV Coinfection
Keywords: Metformin
Tuberculosis
Anti-Tuberculosis Treatment (ATT)
Anti-Viral Therapy (ART)
Lead sponsor: University of Massachusetts, Worcester
Sponsor class: OTHER
Collaborators: name: National Institute of Allergy and Infectious Diseases (NIAID)
name: Aurum Institute
name: A*STAR Infectious Diseases Labs
name: University of Cape Town
name: Wits Health Consortium (Pty) Ltd
First posted: 2021-06-18
Enrollment: 112
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants are assigned to one of two or more groups, Standard ATT or Standard ATT plus Metformin in parallel for 11 weeks starting 1 week after ATT initiation.
Primary purpose: TREATMENT

Brief summary: The METHOD study will examine whether adding metformin to standard antibiotic treatment for tuberculosis (TB) in people with HIV is safe and well tolerated. The study will also test if adding metformin clears the infection more quickly and with less lung damage. When enrolled, participants will have an equal chance of being in the group that takes standard TB medicines alone or in the group that also takes metformin. Participants will have a chance to be put on either: 1) standard TB medicines (isoniazid, rifampicin, ethambutol and pyrazinamide for two months, continuing isoniazid and rifampin for four more months) only; or 2) the same standard TB medicines plus metformin. Participants randomized to the metformin arm will take metformin for eleven weeks, starting one week after starting the standard TB medicines. In addition to monitoring for side effects, all participants will have studies of drug levels and lung and immune function.

Detailed description: The METHOD trial is a Phase II A randomized, open-label trial of metformin added to standard anti-tuberculosis treatment (ATT) and anti-retroviral therapy (ART) in TB/HIV co-infected patients. HIV-positive adults (treated or ART-naïve) newly diagnosed with sputum culture-positive, drug-sensitive pulmonary TB will be recruited to and enrolled in the study. All participants in the interventional study will take standard ATT for drug-sensitive pulmonary TB starting at enrollment. Participants in the metformin arm will begin taking metformin 1 week later and metformin will be stopped on week-12. The "omics" control group will include those (treated or ART-naïve) without evidence of active TB. The total cohort is sample size N=112, comprising 56 participants each in two parallel study arms (standard therapy or standard therapy plus metformin) with the goal of retaining 100 participants with evaluable data for analysis. The duration of the METHOD trial is 5 years. The duration of individual participation in the interventional arms of the study is 36 weeks, not including an initial period of screening over an interval of up to 14 additional days prior to study enrollment. The final clinic visit coincides with the completion of ATT at week-24. The final follow-up contact is a phone interview at week-36. Ten consenting participants from each study arm (n=20 total) will have intensive pharmacokinetic/pharmacodynamic (PK/PD) sampling. The remaining 92 participants will have sparse PK/PD sampling.

Eligibility criteria: Inclusion Criteria:

1. Age 18 through 65 years.
2. HIV-1 seropositive status prior to or after screening.
3. Chest radiograph compatible with pulmonary TB.
4. Positive sputum Xpert TB/RIF or Ultra with one CT \<25.
5. RIF susceptibility diagnosed by Xpert TB/RIF or Ultra.
6. Residence within study catchment area.
7. If female of childbearing potential, willing to use contraception for the duration of study participation (Criteria for childbearing potential and for acceptable contraception). If male, willing to use condoms for the duration of metformin treatment plus 3 months after stopping metformin.
8. Able and willing to provide informed consent. Inclusion criteria 1, 2, 6, 7, and 8 also apply to the control group.

Exclusion criteria:

1. Any condition for which participation in the trial, as judged by the investigator, could compromise the well-being of the subject or prevent, limit or confound protocol-specified assessments.
2. Is critically ill, and in the judgment of the investigator has a diagnosis likely to result in death during the trial or the follow-up period.
3. TB meningitis or other forms of severe TB with high risk of a poor outcome as judged by the investigator.
4. Pregnant or breastfeeding.
5. Resistance to any first-line ATTB drug demonstrated by susceptibility testing.
6. More than 14 days ATT for the current episode of TB, prior to enrollment.
7. Taking any fluoroquinolone antibiotic.
8. History of diabetes mellitus or fasting blood glucose \>7.0 mmol/L on screening evaluation
9. History of congestive heart failure, chronic liver disease, diabetes, autoimmune disease or malignancy.
10. Consumption of \>28 units (men) OR \>21 units (women) of alcohol/week (see Protocol Appendix; Alcohol Pre-Screening Checklist).
11. Use of metformin within 1 year prior to enrollment.
12. History of sensitivity to metformin.
13. Acute or chronic metabolic acidosis based on reported medical history or laboratory tests performed on screening.
14. Body mass index (BMI) \<17.0 kg/m2 on screening evaluation.
15. Peripheral blood CD4 T cell count \<50 cells/mm3 on screening evaluation.
16. Hemoglobin \<9 g/dL for males, and \<8 g/dL (women) for females on screening evaluation.
17. Platelet count \<50,000/mm3 on screening evaluation.
18. Absolute neutrophil count \<750 cells/mm3 on screening evaluation.
19. Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m2 calculated by the CKD-EPI equation.
20. Serum bicarbonate \<18 mmol/L on screening evaluation.
21. AST or ALT ≥3 times the upper limit of normal (ULN) on screening evaluation.
22. Hepatitis B surface antigen positive.
23. Enrollment in another interventional study at any time during participation in the METHOD trial.
24. Imprisonment at the time of or after enrollment in the METHOD trial.
25. Diagnosis of active COVID-19 at the time of screening or high suspicion of active COVID-19 disease during screening.

Exclusion criteria 1, 2, 4, 5, 7, 8-11, 13-25 also apply to participants in the omics control group. In addition, a positive sputum Xpert TB/RI, Mtb culture or any radiographic evidence of any pulmonary infectious disease process is exclusion criteria for the omics control group.

Primary outcomes:
measure: Safety and tolerability of metformin as measured by the number of grade 3 or higher gastrointestinal (GI) adverse events
timeFrame: Up to 16 weeks
Secondary outcomes:
measure: Metformin added to standard ATT improves respiratory health as measured by radiographic score
timeFrame: Change in baseline radiographic score at week 24
measure: Metformin added to standard ATT improves respiratory health as measured by 6-minute Walk Test (6MWT) as assessed by distance x 02 saturation (2° endpoint)
timeFrame: Change in baseline 6MWT at week 24
measure: Metformin added to standard ATT improves respiratory health as measured by spirometry: Forced Vital Capacity (FVC)
timeFrame: Change in baseline spirometric value at week 24
measure: Metformin added to standard ATT improves respiratory health as measured by spirometry: Forced Expiratory Volume (FEV1%) (2° endpoint)
timeFrame: Change in baseline spirometric value at week 24
measure: Metformin added to standard ATT improves respiratory health as measured by Saint George's Respiratory Questionnaire (SGRQ) assessed by 2° endpoint
timeFrame: Change in baseline SGRQ at week 24
measure: Metformin added to standard ATT improves HIV outcomes as measured by HIV viral load
timeFrame: Up to 24 weeks
measure: Metformin added to standard ATT improves HIV outcomes as measured by CD4
timeFrame: Up to 24 weeks
measure: Metformin added to standard ATT improves HIV outcomes as measured by T cell count
timeFrame: Up to 24 weeks
measure: Metformin added to standard ATT improves TB treatment outcomes
timeFrame: Up to 24 weeks
Other outcomes:
measure: Efficacy of metformin as measured by time to sputum conversion in Mycobacterial Growth Indicator Tube (MGIT)
timeFrame: Up to 24 weeks
Locations:
city: Johannesburg
country: South Africa
facility: Tembisa Clinical Research Centre-The Aurum Institute
state: Gauteng
city: Port Elizabeth
country: South Africa
facility: Isango Lethemba TB Research Unit
Study officials:
affiliation: Aurum Institute
name: Robert S Wallis, MD, FIDSA
role: STUDY_CHAIR
affiliation: The University of Massachusetts Chan Medical School
name: Hardy Kornfeld, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Divecha N, Mansouri H, Peat D, Cope G, Partridge L, McDonald CJ. Isoprenaline-induced and constitutive members of a proline-rich protein sub-group from mouse parotid glands studied with monoclonal antibody NAL1. J Mol Endocrinol. 1989 Jul;3(1):7-14. doi: 10.1677/jme.0.0030007.
citation: Chap Z, Ishida T, Jones RH, Pena JR, Vinik A, Field JB. Hepatic extraction of somatostatin in conscious dogs. Am J Physiol. 1988 Feb;254(2 Pt 1):E214-21. doi: 10.1152/ajpendo.1988.254.2.E214.
citation: Shperling ID. [A rare case of implantation metastases of a melanoma to the mitral valve with embolism of the coronary artery, infarct and myocardial rupture]. Arkh Patol. 1989;51(6):70-2. Russian.
citation: Singhal A, Jie L, Kumar P, Hong GS, Leow MK, Paleja B, Tsenova L, Kurepina N, Chen J, Zolezzi F, Kreiswirth B, Poidinger M, Chee C, Kaplan G, Wang YT, De Libero G. Metformin as adjunct antituberculosis therapy. Sci Transl Med. 2014 Nov 19;6(263):263ra159. doi: 10.1126/scitranslmed.3009885.
citation: Strate SM, Rutledge JC, Weinberg AG. Delayed development of angiosarcoma in multinodular infantile hepatic hemangioendothelioma. Arch Pathol Lab Med. 1984 Dec;108(12):943-4. No abstract available.
citation: Dubarry JJ, Auche Y, Bernard JP, Fontanges X. [Therapeutic application of anabolising drugs in gastroenterology. Apropos of Primobolan-Depot]. Gaz Med Fr. 1965 Sep 10;72(17):2896-8. No abstract available. French.
citation: Kumar NP, Moideen K, Viswanathan V, Shruthi BS, Sivakumar S, Menon PA, Kornfeld H, Babu S. Elevated levels of matrix metalloproteinases reflect severity and extent of disease in tuberculosis-diabetes co-morbidity and are predominantly reversed following standard anti-tuberculosis or metformin treatment. BMC Infect Dis. 2018 Jul 25;18(1):345. doi: 10.1186/s12879-018-3246-y.
citation: Padmapriyadarsini C, Bhavani PK, Natrajan M, Ponnuraja C, Kumar H, Gomathy SN, Guleria R, Jawahar SM, Singh M, Balganesh T, Swaminathan S. Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial. BMJ Open. 2019 Mar 1;9(3):e024363. doi: 10.1136/bmjopen-2018-024363.
citation: Bianchi Porro G, Parente F. Recent developments in peptic ulcer treatment. Scand J Gastroenterol Suppl. 1988;146:159-65. doi: 10.3109/00365528809099142.
citation: Vincenzoni M, Brizi MG, De Vivo D, Romani M, Del Grosso C, Vecchioli A. Computerised management of the radio-diagnostic ward: considerations on our three years experience. Rays. 1985 May-Aug;10(2):57-61. No abstract available.
citation: Ralph AP, Ardian M, Wiguna A, Maguire GP, Becker NG, Drogumuller G, Wilks MJ, Waramori G, Tjitra E, Sandjaja, Kenagalem E, Pontororing GJ, Anstey NM, Kelly PM. A simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary tuberculosis. Thorax. 2010 Oct;65(10):863-9. doi: 10.1136/thx.2010.136242.
citation: Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010 Apr 14;2010(4):CD002967. doi: 10.1002/14651858.CD002967.pub4.
citation: Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011 Feb;50(2):81-98. doi: 10.2165/11534750-000000000-00000.
citation: Chandel NS, Avizonis D, Reczek CR, Weinberg SE, Menz S, Neuhaus R, Christian S, Haegebarth A, Algire C, Pollak M. Are Metformin Doses Used in Murine Cancer Models Clinically Relevant? Cell Metab. 2016 Apr 12;23(4):569-70. doi: 10.1016/j.cmet.2016.03.010. No abstract available.
citation: Song IH, Zong J, Borland J, Jerva F, Wynne B, Zamek-Gliszczynski MJ, Humphreys JE, Bowers GD, Choukour M. The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects. J Acquir Immune Defic Syndr. 2016 Aug 1;72(4):400-7. doi: 10.1097/QAI.0000000000000983.
citation: Te Brake LHM, Yunivita V, Livia R, Soetedjo N, van Ewijk-Beneken Kolmer E, Koenderink JB, Burger DM, Santoso P, van Crevel R, Alisjahbana B, Aarnoutse RE, Ruslami R; TANDEM Consortium. Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients. Clin Pharmacol Ther. 2019 Mar;105(3):730-737. doi: 10.1002/cpt.1232. Epub 2018 Oct 29.
citation: Allard M. My solidarity towards patients. Interview by Guylaine Campion. Infirm Aux. 1985 Oct;58(2):15-6, 32-3. No abstract available. English, French.
citation: Wulffele MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, Donker AJ, Stehouwer CD. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med. 2003 Nov;254(5):455-63. doi: 10.1046/j.1365-2796.2003.01213.x.
citation: Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf. 2010 Sep 1;33(9):727-40. doi: 10.2165/11536790-000000000-00000.
citation: Booysen HL, Woodiwiss AJ, Raymond A, Sareli P, Hsu HC, Dessein PH, Norton GR. Chronic kidney disease epidemiology collaboration-derived glomerular filtration rate performs better at detecting preclinical end-organ changes than alternative equations in black Africans. J Hypertens. 2016 Jun;34(6):1178-85. doi: 10.1097/HJH.0000000000000924.
citation: DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: Current perspectives on causes and risk. Metabolism. 2016 Feb;65(2):20-9. doi: 10.1016/j.metabol.2015.10.014. Epub 2015 Oct 9.
citation: Brackett CC. Clarifying metformin's role and risks in liver dysfunction. J Am Pharm Assoc (2003). 2010 May-Jun;50(3):407-10. doi: 10.1331/JAPhA.2010.08090.
citation: Wallis RS, Peppard T. Early Biomarkers and Regulatory Innovation in Multidrug-Resistant Tuberculosis. Clin Infect Dis. 2015 Oct 15;61Suppl 3:S160-3. doi: 10.1093/cid/civ612.
citation: Hoft DF, Worku S, Kampmann B, Whalen CC, Ellner JJ, Hirsch CS, Brown RB, Larkin R, Li Q, Yun H, Silver RF. Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity. J Infect Dis. 2002 Nov 15;186(10):1448-57. doi: 10.1086/344359. Epub 2002 Oct 23.
citation: Bone LB, Johnson KD. Treatment of tibial fractures by reaming and intramedullary nailing. J Bone Joint Surg Am. 1986 Jul;68(6):877-87.
citation: Kosinska M. [Nursing decisions--their scope and limitations]. Pieleg Polozna. 1988;(4):6-7. No abstract available. Polish.
citation: Aperis G, Paliouras C, Zervos A, Arvanitis A, Alivanis P. Lactic acidosis after concomitant treatment with metformin and tenofovir in a patient with HIV infection. J Ren Care. 2011 Mar;37(1):25-9. doi: 10.1111/j.1755-6686.2011.00209.x.
citation: Ortiz-Brizuela E, Perez-Patrigeon S, Recillas-Gispert C, Gomez-Perez FJ. Lactic Acidosis Complicating Metformin and Non-Nucleoside Reverse Transcriptase Inhibitor Combination Therapy: A Smoldering Threat in the Post-HAART Era. Rev Invest Clin. 2015 Jul-Aug;67(4):273-4.
citation: Ledvina M, Bartos F, Hroch M. Formation of hydroxyproline-containing proteins by fibroblasts in tissue culture (chick embryo fibroblasts-L-cells- 14 C proline-labelling). Folia Biol (Praha). 1972;18(5):327-30. No abstract available.
citation: Naccarato M, Yoong D, Fong IW. Dolutegravir and metformin: a case of hyperlactatemia. AIDS. 2017 Sep 24;31(15):2176-2177. doi: 10.1097/QAD.0000000000001617. No abstract available.
citation: Cho SK, Yoon JS, Lee MG, Lee DH, Lim LA, Park K, Park MS, Chung JY. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Clin Pharmacol Ther. 2011 Mar;89(3):416-21. doi: 10.1038/clpt.2010.266. Epub 2011 Jan 26.
citation: Roberts C, Nylander AE, Jayaramachandran S. Orbital cellulitis complicating isolated unilateral sphenoidal sinusitis: importance of the CT scan. Br J Ophthalmol. 1989 Sep;73(9):769-70. doi: 10.1136/bjo.73.9.769.
citation: Doyle MA, Singer J, Lee T, Muir M, Cooper C. Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co-infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial. Trials. 2016 Jul 20;17(1):331. doi: 10.1186/s13063-016-1454-6.
citation: Cameron AR, Morrison VL, Levin D, Mohan M, Forteath C, Beall C, McNeilly AD, Balfour DJ, Savinko T, Wong AK, Viollet B, Sakamoto K, Fagerholm SC, Foretz M, Lang CC, Rena G. Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status. Circ Res. 2016 Aug 19;119(5):652-65. doi: 10.1161/CIRCRESAHA.116.308445. Epub 2016 Jul 14.
citation: Lazarus B, Wu A, Shin JI, Sang Y, Alexander GC, Secora A, Inker LA, Coresh J, Chang AR, Grams ME. Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function: A Community-Based Cohort Study. JAMA Intern Med. 2018 Jul 1;178(7):903-910. doi: 10.1001/jamainternmed.2018.0292.
citation: Moyo S, Bussmann H, Mangwendeza P, Dusara P, Gaolathe T, Mine M, Musonda R, van Widenfelt E, Novitsky V, Makhema J, Marlink RG, Essex M, Wester CW. Validation of A Point-of-Care Lactate Device For Screening At-Risk Adults Receiving Combination Antiretroviral Therapy In Botswana. J Antivir Antiretrovir. 2011 Oct;3(4):45-48. doi: 10.4172/jaa.1000034. Epub 2011 Sep 20.